Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
WILMINGTON, Del., Jan. 15, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of XBiotech Inc. (NASDAQ:XBIT)?
- Did you purchase your shares pursuant and/or traceable to the April 15, 2015 initial public offering, or between April 15, 2015 and November 23, 2015, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of XBiotech Inc. (“XBiotech” or the “Company”) (NASDAQ:XBIT) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the Western District of Texas on behalf of all persons or entities that purchased the common stock of XBiotech between April 15, 2015 and November 23, 2015, inclusive (the “Class Period”) alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers. A separate complaint has been filed in the Superior Court of the State of California on behalf of all persons or entities that acquired XBiotech shares pursuant or traceable to its initial public offering (“IPO”) commenced on or about April 15, 2015, alleging violations of the Securities Exchange Act of 1933 against the Company and certain of its officers.
If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of XBiotech in the April 15, 2015 offering, or during the period April 15, 2015 and November 23, 2015, inclusive, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/xbiotech-inc-xbit.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
